XCancer

64Cu-LLP2A for Imaging Hematologic Malignancies

Description:

This phase of the protocol (protocol part B), seeks to evaluate the new formulation in healthy normal volunteers to confirm the new formulation provides comparable human dosimetry to which was seen and published in protocol part A. Additionally, the new formulation will be studied utilizing an expanded patient population to include patients with confirmed diagnosis of multiple myeloma (MM), low-grade lymphoma, or MM and lymphoma patients who are status post bone marrow transplant (BMT) with negative imaging and suspected recurrence.

Sponsor:

Washington University School of Medicine

Phase:

Early Phase 1

Contacts:

Farrokh Dehdashti, M.D. (PRINCIPAL_INVESTIGATOR)

Jennifer Frye, CNMT, CCRC (CONTACT)

fryej@wustl.edu

314-747-1604

Farrokh Dehdashti, M.D. (CONTACT)

dehdashtif@wustl.edu

314-362-1474

Government Study Link:

NCT06636175 - Click here to see study on

ClinicalTrials.gov

LLP2A

Isotope(s):
Target(s):
  • Very Late Antigen-4 (integrin α4β1)
Ligand Class: Small Molecules
Chelator: CB-TE1A1P
Inclusion
  • Clinical or pathologically defined MM or lymphoma including both newly diagnosed, relapsed or refractory disease:
  • Multiple Myeloma defined in accordance with the International Myeloma Working Group criteria
  • Low-grade lymphoma, including the following subtypes: follicular lymphoma, marginal zone lymphoma, lymphoplasmacytic lymphoma, small lymphocytic lymphoma/chronic lymphocytic leukemia
Exclusion

Exclusion Criteria Not Yet Provided